We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Expression Tests Helps Tailor Cancer Treatments

By LabMedica International staff writers
Posted on 22 May 2013
Breast cancers contain many different cell types with different patterns of gene expression which when tested for can help tailor cancer treatments to individual patients.

Breast carcinomas contain a variety of diverse cell types and an important result of this heterogeneity is that different biopsy specimens from a single breast cancer tumor can exhibit significant variability in genes expression.

Oncologists from the Maria Sklodowska-Curie Memorial Cancer Center (Warsaw, Poland) took a total of 78 different biopsies from 26 individual tumors to assess the degree of genomic variation, and its impact on a set of 32 different prognostic and predictive multigene signatures. More...
The team performed gene expression profiling on their 78 samples using oligonucleotide microarrays.

Overall, they found that the gene expression profiles of the cores were variable, and in at least five patients, this heterogeneity was substantial. However, when they analyzed a number of multigene signatures selected from previous studies, this heterogeneity was considerably less significant. The gene sets differed in their variance between biopsies. The most pronounced heterogeneity was observed in immune response-related genes, while the least heterogeneous were the classifiers based on genes selected by advanced bioinformatical methods from both cell culture trials and patient tissues.

Michał Jarząb, MD, the senior author of the study said, “Overall, the heterogeneity among the potentially predictive genes was small enough and we conclude that this factor should not prohibit their effective use in clinical practice. Our study confirms that it is possible to address tumor heterogeneity when carrying out routine diagnostic procedures in patients. Our results may help to introduce the better tailoring of preoperative treatment."

Angelo Di Leo, MD, PhD, from the Tuscan Cancer Institute (Florence, Italy) said, “The study is innovative because it is one of the first to address the question of intratumor heterogeneity. It means that not all the cells from the same tumor have the same characteristics, and if we want to have a clear picture of the tumor biology we should not limit the evaluation of tumor markers to one area of the tumor itself." The studies were presented at the Annual IMPAKT Breast Cancer Conference, held May 2–4, 2013, in Brussels (Belgium).

Related Links:

Maria Skłodowska-Curie Memorial Cancer Center
Tuscan Cancer Institute



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
Laboratory Software
ArtelWare
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.